China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone86-10-6598-3111
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$466.88 million
Profitability
Miscellaneous
Employees2,187
Next Earnings Date8/2/2019 (Estimated)
OptionableOptionable
China Biologic Products (NASDAQ:CBPO) Frequently Asked Questions
What is China Biologic Products' stock symbol?
China Biologic Products trades on the NASDAQ under the ticker symbol "CBPO."
How were China Biologic Products' earnings last quarter?
China Biologic Products Holdings Inc (NASDAQ:CBPO) announced its quarterly earnings results on Friday, May, 10th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.99 by $0.12. The biopharmaceutical company had revenue of $129.78 million for the quarter, compared to analyst estimates of $119.50 million. China Biologic Products had a net margin of 27.71% and a return on equity of 8.81%. During the same quarter last year, the business earned $1.21 EPS. View China Biologic Products' Earnings History.
When is China Biologic Products' next earnings date?
What price target have analysts set for CBPO?
3 analysts have issued 12-month price objectives for China Biologic Products' stock. Their forecasts range from $62.00 to $88.00. On average, they anticipate China Biologic Products' share price to reach $78.00 in the next twelve months. This suggests that the stock has a possible downside of 18.6%. View Analyst Price Targets for China Biologic Products.
What is the consensus analysts' recommendation for China Biologic Products?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for China Biologic Products in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for China Biologic Products.
Has China Biologic Products been receiving favorable news coverage?
Headlines about CBPO stock have been trending neutral on Tuesday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. China Biologic Products earned a media sentiment score of 0.5 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for China Biologic Products.
Are investors shorting China Biologic Products?
China Biologic Products saw a decrease in short interest in May. As of May 15th, there was short interest totalling 1,457,700 shares, a decrease of 17.3% from the April 15th total of 1,763,300 shares. Based on an average daily volume of 280,200 shares, the short-interest ratio is presently 5.2 days. Currently, 6.8% of the company's stock are short sold. View China Biologic Products' Current Options Chain.
Who are some of China Biologic Products' key competitors?
Some companies that are related to China Biologic Products include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), BIO-TECHNE (TECH), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), argenx (ARGX), Spark Therapeutics (ONCE), Repligen (RGEN), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP) and Acceleron Pharma (XLRN).
What other stocks do shareholders of China Biologic Products own?
Who are China Biologic Products' key executives?
China Biologic Products' management team includes the folowing people:
- Mr. Ming Yang, Chief Financial Officer (Age 47)
- Mr. Ming Yin, Sr. VP (Age 41)
- Ms. Zhijing Liu, Corp. VP (Age 65)
- Mr. Gang Yang, Corp. VP & GM of Guizhou Taibang (Age 54)
- Dr. Bing Li Ph.D., CEO & Director (Age 51)
Who are China Biologic Products' major shareholders?
China Biologic Products' stock is owned by a number of of institutional and retail investors. Top institutional investors include FIL Ltd (1.32%), Greenwoods Asset Management Ltd (1.22%), FMR LLC (1.07%), Maso Capital Partners Ltd (0.42%), Wasatch Advisors Inc. (0.37%) and Dalton Investments LLC (0.29%). View Institutional Ownership Trends for China Biologic Products.
Which institutional investors are selling China Biologic Products stock?
CBPO stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Myriad Asset Management Ltd., Wasatch Advisors Inc., TT International, First Trust Advisors LP, Comerica Bank and California Public Employees Retirement System. View Insider Buying and Selling for China Biologic Products.
Which institutional investors are buying China Biologic Products stock?
CBPO stock was acquired by a variety of institutional investors in the last quarter, including Greenwoods Asset Management Ltd, Nikko Asset Management Americas Inc., Dalton Investments LLC, FIL Ltd, Maso Capital Partners Ltd, Alpine Global Management LLC, Parametrica Management Ltd and Laurion Capital Management LP. View Insider Buying and Selling for China Biologic Products.
How do I buy shares of China Biologic Products?
Shares of CBPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is China Biologic Products' stock price today?
One share of CBPO stock can currently be purchased for approximately $95.78.
How big of a company is China Biologic Products?
China Biologic Products has a market capitalization of $3.77 billion and generates $466.88 million in revenue each year. The biopharmaceutical company earns $128.06 million in net income (profit) each year or $4.02 on an earnings per share basis. China Biologic Products employs 2,187 workers across the globe.View Additional Information About China Biologic Products.
What is China Biologic Products' official website?
How can I contact China Biologic Products?
China Biologic Products' mailing address is 18TH FL JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD CHAOYANG DISTRICT, BEIJING F4, 100125. The biopharmaceutical company can be reached via phone at 86-10-6598-3111 or via email at [email protected]
MarketBeat Community Rating for China Biologic Products (NASDAQ CBPO)
MarketBeat's community ratings are surveys of what our community members think about China Biologic Products and other stocks. Vote "Outperform" if you believe CBPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
